Rising obesity prevalence has led to a high-risk group with both disorders. We assessed mortality risk associated with sarcopenia and sarcopenic obesity in elders. Mean age was 70.6±0.2 years and ...

随着全球老龄化趋势加剧以及生活方式的改变，肌少症和肥胖的患病率持续攀升。肌少症作为一种与年龄相关的骨骼肌功能下降疾病，逐渐成为影响老年人生活质量的主要威胁。而肥胖不仅与代谢紊乱、心血管疾病等多种慢性病密切相关，还会掩盖肌少症的存在，使患者在日常生活中 ...

在如今的健康话题中，肌少症性肥胖（Sarcopenic Obesity, SO）所引发的关注愈发成为焦点。我们时常把瘦与胖看作截然不同的两类身体状态，却未曾想到，现代医学告诉我们，两者可以奇妙地并存于一个人的身体中，形成复杂且棘手的健康问题。那么，什么是肌少症性肥胖呢？它又为何会成为现代社会中不容忽视的健康危机？

Data from SURMOUNT-OSA and a prespecified analysis of the SELECT trial were among the biggest obesity studies in 2024. Researchers also examined differences in physical activity benefits between ...

About Veru Inc. Veru is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic diseases, oncology, and ARDS. The Company’s drug ...

Skinny fat’ refers to individuals with low muscle mass but high body fat, especially visceral fat. Despite appearing slim, they face health risks like type 2 diabetes, heart disease, and bone weakness ...

New Delhi, May 27 (ANI): According to new research by Juntendo University, scientists linked dementia in elderly people with sarcopenic obesity. The findings of the research were published in the ...

She was the classic case of being skinny fat, a person who has normal body weight but has a high percentage of body fat ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

“Beginning as early as the [fourth] decade of life, evidence suggests that skeletal muscle mass and skeletal muscle strength decline in a linear fashion, with up to 50% of mass being lost by the ...

The Phase 2b, multicenter, double-blind, placebo-controlled, randomized, dose-finding clinical trial is designed to evaluate the safety and efficacy of enobosarm 3mg, enobosarm 6mg, or placebo as a ...